Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03419234 · ClinicalTrials.gov registry record · Phase 2

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Stage IV Prostate Adenocarcinoma AJCC v7, sponsored by ECOG-ACRIN Cancer Research Group.

Active
Registry status
Phase 2
Development phase
223
Enrollment target
20
Study locations

NCT03419234 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Stage IV Prostate Adenocarcinoma AJCC v7 that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 223 participants, above the 73-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (205% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03419234, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Stage IV Prostate Adenocarcinoma AJCC v7, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
223 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel and prednisone may help kill more tumor cells.

Conditions Studied

Castration-Resistant Prostate Carcinoma Stage IV Prostate Adenocarcinoma AJCC v7 Prostate Carcinoma Metastatic in the Bone Castration Levels of Testosterone Metastatic Prostate Carcinoma in the Soft Tissue

Interventions

  • DRUG Prednisone
  • DRUG Abiraterone Acetate
  • DRUG Cabazitaxel
  • DRUG Androgen deprivation therapy

Study Locations (20)

California

  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • PCR Oncology - Arroyo Grande
  • Sutter Auburn Faith Hospital - Auburn
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • Alta Bates Summit Medical Center-Herrick Campus - Berkeley
  • Mills-Peninsula Medical Center - Burlingame
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
  • Eden Hospital Medical Center - Castro Valley
  • Adventist Health Cancer Care Center Chico - Chico
  • Sutter Davis Hospital - Davis
  • Epic Care-Dublin - Dublin
  • Kaiser Permanente Dublin - Dublin
  • Bay Area Breast Surgeons Inc - Emeryville

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
  • John L McClellan Memorial Veterans Hospital - Little Rock

Arizona

  • CTCA at Western Regional Medical Center - Goodyear
  • Kingman Regional Medical Center - Kingman

Alaska

  • Fairbanks Memorial Hospital - Fairbanks

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2018-04-26
Est. Completion 2026-04-01
Phase Phase 2

Sponsor

ECOG-ACRIN Cancer Research Group

75 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03419234

The ClinicalTrials.gov registry entry for NCT03419234 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (205% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.

NCT03419234 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Arizona.

Frequently Asked Questions

What is clinical trial NCT03419234 about?

NCT03419234 is a clinical study titled "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel". This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can ca...

What is the current status of trial NCT03419234?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2018-04-26. Estimated completion is 2026-04-01.

What conditions does trial NCT03419234 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Stage IV Prostate Adenocarcinoma AJCC v7, Prostate Carcinoma Metastatic in the Bone, Castration Levels of Testosterone, Metastatic Prostate Carcinoma in the Soft Tissue.

What interventions are being tested in trial NCT03419234?

The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG), Cabazitaxel (DRUG), Androgen deprivation therapy (DRUG).

Who is sponsoring clinical trial NCT03419234?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03419234 being conducted?

This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Stage IV Prostate Adenocarcinoma AJCC v7

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.